Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid
Oncology Letters · 02.02.2024 · 27 (4)
DOI: 10.3892/ol.2024.14272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Letters, online erschienen am 02.02.2024. Verfasst von Yutaka Nakano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The efficacy of next-generation sequencing (NGS) of tumor-derived DNA from intraoperative peritoneal washing fluid (IPWF) of patients with pancreatic ductal adenocarcinoma (PDAC) who intend to undergo curative resection remains unclear. The aim of the present study was to evaluate whether genomic mutations in tumor-derived DNA from IPWF samples of patients with PDAC who intend to undergo curative resection could be detected using NGS. A total of 12 such patients were included in this study. Cytology of IPWF (CY) was assessed and NGS of genomic tumor-derived DNA from the IPWF was performed to determine whether genomic mutations could be detected in these patient samples. A total of 2 patients (16.7%) had a CY(+) status and 1 patient (8.3%) showed intraoperative macro-peritoneal dissemination; 11 patients underwent radical surgery. Actionable gene alterations were detected in 8 (80.0%) out of the 10 patients with CY(-) status based on NGS of IPWF samples, and 3 (37.5%) patients among those with actionable gene mutations identified from IPWF samples underwent peritoneal dissemination after surgery within ~12 months. The most common genomic mutation was in KRAS (9 patients, 75.0%), followed by TP53 (3 patients, 25.0%), SMAD4 (1 patient, 8.3%) and CDKN2A (1 patient, 8.3%). These findings indicated that the genomic mutations identified in tumor-derived DNA from IPWF samples of patients with PDAC with a CY(-) status who intend to undergo curative resection are potential biomarkers for predicting the recurrence of early peritoneal dissemination.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Genomics Unit, Keio University School of Medicine, Tokyo 160-8582, Japan.
- Department of Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Zitieren
APA
Nakano, Y., Shimane, G., Nakamura, K., Takamatsu, R., Aimono, E., Yagi, H., Abe, Y., Hasegawa, Y., Hori, S., Tanaka, M., Masugi, Y., Kitago, M., Nishihara, H., & Kitagawa, Y. (2024). Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Oncology Letters, 27(4). https://doi.org/10.3892/ol.2024.14272
Vancouver
Nakano Y, Shimane G, Nakamura K, Takamatsu R, Aimono E, Yagi H, et al. Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid. Oncology Letters. 2024;27(4). doi:10.3892/ol.2024.14272
BibTeX
@article{Nakano2024,
author = {Nakano, Yutaka and Shimane, Gaku and Nakamura, Kohei and Takamatsu, Reika and Aimono, Eriko and Yagi, Hiroshi and Abe, Yuta and Hasegawa, Yasushi and Hori, Shutaro and Tanaka, Masayuki and Masugi, Yohei and Kitago, Minoru and Nishihara, Hiroshi and Kitagawa, Yuko},
title = {Next‑generation sequencing to identify genetic mutations in pancreatic cancer using intraoperative peritoneal washing fluid},
journal = {Oncology Letters},
year = {2024},
volume = {27},
number = {4},
doi = {10.3892/ol.2024.14272}
}
EUVIMED